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Background: Infliximab, a TNF-alpha antagonist, has shown efficacy in the treatment of
sarcoidosis. Since corticosteroids inhibit TNF-alpha expression, we postulated that sarcoidosis
patients receiving a sufficient corticosteroid dose may have an attenuated response to the
addition of infliximab.
Methods: We analyzed data from a previous randomized double blind prospective trial of inflix-
imab versus placebo for chronic pulmonary sarcoidosis. The effect of the maintenance corti-
costeroid dose on the change in FVC % predicted between 0 and 24 weeks (DFVC%pred0-24)
was analyzed in two ways. First, the mean DFVC%pred0-24 was calculated for the placebo
and infliximab groups using three different daily prednisone equivalent dose thresholds: a)
<10 mg versus 10 mg; b) <15 mg versus 15 mg; c) <20 mg versus 20 mg. Second, in both
the placebo and infliximab groups, a correlation coefficient was calculated between the main-
tenance corticosteroid dose and DFVC%pred0-24.
Results: Both the group that received infliximab and either a maintenance daily dose of
<10 mg of prednisone and the group receiving 10 mg had a significant increase in FVC%
pred0-24. However, both the groups that received infliximab and a corticosteroid dose oflmonary and Critical Care Medicine MC-91, Albany Medical College, Albany, NY 12208, USA. Tel.: þ1
c.edu (M.A. Judson).
3 Elsevier Ltd. All rights reserved.
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190 M.A. Judson et al.>15 mg of prednisone and 20 mg of prednisone did not demonstrate a significant DFVC%
pred0-24. For the placebo group, there was no significant correlation between the corticoste-
roid dose and the DFVC%pred0-24. For the infliximab group, there was a significant correlation
(p Z 0.0097) between higher corticosteroid dose and less improvement in FVC%pred0-24.
Conclusion: Our results suggest that infliximab adds minimal potential benefit to corticoste-
roids for pulmonary sarcoidosis at doses above 15e20 mg/day of prednisone.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Infliximab has shown promise for the treatment of pulmo-
nary and extrapulmonary sarcoidosis. In a prospective
randomized clinical trial of chronic pulmonary sarcoidosis
patients, infliximab improved the forced vital capacity
(FVC) and lessened the degree of extrapulmonary sarcoid-
osis involvement by a statistically significant amount
compared to those who received placebo [1,2].
Infliximab is a chimeric monoclonal antibody directed
against tumor necrosis factor alpha (TNF-a). There is a
sound rationale for using infliximab in the treatment of
sarcoidosis because TNF-a is released by macrophages in
patients with sarcoidosis [3], and TNF-a is thought to be
integrally involved in the development of the sarcoid
granuloma [4e6].
Although infliximab therapy has been used for the
treatment of sarcoidosis for several years, there has been
minimal attention paid to the effect of this drug in
different subsets of sarcoidosis patients including those
with specific organ involvement, specific demographic
characteristics, and specific doses of additional other anti-
sarcoidosis medications. We had anecdotally observed in
our clinical practices that infliximab often failed to provide
additional benefit to patients with pulmonary sarcoidosis
who were receiving 20 mg of daily prednisone equivalent.
Corticosteroids are recognized as the drug of choice for
pulmonary sarcoidosis [7e9]. Corticosteroids have a broad
spectrum of anti-inflammatory effects, including inhibiting
TNF-a expression [10]. Since both infliximab and cortico-
steroids impair the activity of TNF-a, it is possible that
pulmonary sarcoidosis patients who are receiving cortico-
steroids as a maintenance medication may have an atten-
uated response to infliximab. Because data concerning the
effect of the maintenance corticosteroid dose on the
infliximab response was available from a previously per-
formed randomized double blind placebo controlled trial of
infliximab for pulmonary sarcoidosis [1], we decided to
retrieve these data and perform an analysis to determine
the additional benefit of infliximab for pulmonary sarcoid-
osis based on the maintenance corticosteroid dose.
In this current report, we analyzed results of a previous
randomized double blind prospective clinical trial of inflix-
imab versus placebo for the treatment of chronic pulmonary
sarcoidosis [1]. In that trial, a statistically significant
improvement in the FVC at 24 weeks of therapy was found in
those who received infliximab compared to those who
received placebo (2.5% predicted, PZ 0.038). This change in
FVC was the primary endpoint of the trial. During the trial,
subjects were required to be on a stable maintenance dailycorticosteroid dose of10mg of daily prednisone equivalent
and/or other immunosuppressive medications. In the cur-
rent analysis, we sought to determine the impact of the
maintenance corticosteroid dose on the change in % pre-
dicted FVC between 0 and 24 weeks in the infliximab and
placebo groups. Our hypotheses were that a) the placebo
group would not demonstrate a significant change in % pre-
dicted FVC regardless of the maintenance corticosteroid
dose and b) the response of % predicted FVC to 24 weeks of
infliximab treatment would be dependent on the concurrent
maintenance prednisone dose, with higher doses leading to
lower spirometric response.
Methods
The methods of the original trial have been described in
detail elsewhere [1]. In brief, eligible patientswere required
to have histologically proven sarcoidosis, a diagnosis of
sarcoidosis at least one year prior to screening, evidence of
parenchymal lung sarcoidosis on chest radiograph, an FVC of
50% and85% of predicted and a Medical Research Council
dyspnea score of at least grade 1. Patients required treat-
ment with at least 10 mg/d of prednisone or equivalent or
one or more immunosuppressants for 3 months before
screening. Doses of thesemedications had to be stable for1
month before study entry. During the study, the background
medication regimen and doses were to remain stable.
This was a phase 2, multicenter, double-blind, placebo-
controlled study in which patients were randomized in a
1:1:1 ratio to receive intravenous infusions of placebo,
infliximab 3mg/kg, or infliximab5mg/kg atWeeks 0, 2, 6, 12,
18, and 24. A total of 138 patients from 34 centers in North
America and Europe were randomized between September
30, 2003, and August 31, 2004. The primary endpoint was the
change from baseline in the percent of predicted FVC at
Week 24. The initial trial was approved by all Institutional
review boards/ethics committees at the participating sites.
In the current analysis, subjects were included if they
received a daily maintenance corticosteroid dose of greater
than 0 during the trial. Similar to the initial trial, we
combined the 3 mg/kg and 5 mg/kg infliximab groups as
both had a significant positive response in the primary
endpoint compared to placebo as the % predicted FVC
response of the two infliximab doses were not statistically
different from each other. The effect of the maintenance
corticosteroid dose on the change in FVC % predicted be-
tween 0 and 24 weeks was analyzed in two ways. First, the
mean change in % predicted FVC and the 95% confidence
interval between 0 and 24 weeks was calculated for both
the placebo and infliximab groups using three different
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versus 10 mg; b) <15 mg versus 15 mg; c) a) <20 mg
versus 20 mg. If the % predicted FVC was missing at Week
24, it was imputed by the last observation carried forward.
Second, in both the placebo and infliximab groups, a
Spearman correlation coefficient was calculated concern-
ing the association of maintenance corticosteroid dose
through week 24 and change in % predicted FVC between
week 0 and week 24. The maintenance corticosteroid dose
through week 24 was determined as the mean dose
received during that period.
An analysis of covariance was run with the treatment
group as the only factor and baseline % predicted FVC as the
covariate. Least squares means were generated and they
were compared to zero within each treatment group.
Additionally, the mean change from baseline was compared
between the placebo and infliximab groups. Analyses were
performed by using SAS, version 9.2 [SAS Institute Inc.,
Cary, NC 2010].
It should be noted that this analysis used all data
collected from the previous trial. The issue addressed inTable 1 Baseline characteristics of pairs of subgroups based on m
Characteristics Cohort Prednisone dose (mg/d
<10 10
N 122 19 103
Age (mean  SD) 47.0  9.3 42.6  8.3 47.7  9
(P Z 0.02)
Sex
male N (%) 72 (59) 12 (63) 60 (58)
female N (%) 50 (41) 7 (37) 43 (42)
Race
white 83 (68) 13 (68) 70 (68)
black 35 (29) 6 (32) 29 (28)
other 4 (3) 0 4 (4)
% predicted FVC,
mean  SD
68.5  9.6 68.4  8.1 68.6  9
CXR R-score,
mean  SD
3.6  4.1
(N Z 114)
4.8  4.4
(N Z 17)
3.4  4.
(N Z 97
6MWD (meters) 459  113 479  125 456  11
>1 organ involved N (%) 22 (18) 2 (11) 20 (19)
SGRQ score 45.4 þ 18.4 42.1  17.1 46.1  1
MRC dyspnea score
1, N (%) 2 (2) 1 (5) 1 (1)
2, N (%) 54 (44) 7 (37) 47 (46)
3, N (%) 55 (45) 9 (47) 46 (45)
4, N (%) 11 (9) 2 (11) 9 (9)
Corticosteroid dose (mg.)
mean  SD 12.7  7.5 5.1  1.7 14.2  7
median 10 5 10
Received additional
immunosuppressive
medication, N (%)
52 (43) 18 (95) 34 (33)
FVC: forced vital capacity; CXR R-score: chest radiograph reticulation
ratory Questionnaire; MRC: Medical research Council. p-values for race
age were determined by Wilcoxon rank-sum test.this analysis was not a primary or secondary endpoint of
that trial and that trial was not specifically powered to
answer this issue.Results
There were 122 subjects who qualified for this analysis.
Table 1 shows the baseline characteristics of the entire
cohort as well as subgroups divided by cutoff prednisone
dosages (Table 1). Only a few of these characteristics were
statistically different between these subgroups. Patients
that received <10 mg of prednisone had a much higher
frequency of using additional immunosuppressive medica-
tion (Chi square Z 22.5, p < 0.0001). This was in part
because of study entry criteria, which required that pa-
tients who were receiving less than 10 mg pr prednisone be
on an additional immunosuppressant, either hydroxy-
chloroquine or a cytotoxic agent. In addition, there were a
statistically greater percentage of black subjects and sta-
tistically fewer pulmonary opacities as determined by theaintenance daily prednisone thresholds of 10, 15, and 20 mg.
ay)
<15 15 <20 20
87 35 97 25
.3 46.3  9.4 48.7  9.0 46.4  9.5 49.2  8.1
51 (59) 21 (60) 58 (60) 14 (56)
36 (41) 14 (40) 39 (40) 11 (44)
65 (75) 18 (51) 71 (73) 12 (48)
19 (22) 16 (46) 23 (24) 12 (48)
3 (3) 1 (3) 3 (3) 1 (4)
(p Z 0.018) (p Z 0.03)
.8 69.0  9.9 67.5  8.6 69.2  9.6 65.9  8.9
1
)
4.2  4.3
(N Z 79)
2.4  3.5
(N Z 35)
4.1  4.2
(N Z 89)
2.2  3.5
(N Z 25)
(p Z 0.04) (p Z 0.04)
1 465  112 445  115 467  116 428  95
13 (15) 9 (26) 14 (14) 8 (32)
8.7 44.6  17.0 47.7  21.7 44.3  17.6 50.0  21.3
2 (2) 0 2 (2) 0
37 (43) 17 (49) 43 (44) 11 (44)
42 (48) 13 (37) 45 (46) 10 (40)
6 (7) 5 (14) 7 (7) 4 (16)
.3 9.1  2.3 21.9  8.1 9.7  2.9 24.6  8.0
10 20 10 20
41 (47) 11 (31) 44 (45) 8 (32)
score; 6MWD: 6-minute walk distance; SGRQ: St. George Respi-
were determined by Fisher’s exact test. p-values for R-score and
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15 mg of prednisone and 20 prednisone compared to
their counterpart subgroups receiving a lower dosage
(Table 1).
Table 2 shows the change in % predicted FVC between
week 0 and 24 for the placebo and infliximab groups
stratified by less than versus greater than or equal to a daily
corticosteroid maintenance dose of 10 mg, 15 mg, and
20 mg of prednisone equivalent. Groups that received pla-
cebo failed to demonstrate a significant improvement in %
predicted FVC regardless of their maintenance corticoste-
roid dose. Both the group that received infliximab that had
a maintenance corticosteroid dose of <10 mg of daily
prednisone equivalent and the group had 10 mg of pred-
nisone equivalent had a significant increase in % predicted
FVC over the 24 weeks. The groups that received infliximab
that had a maintenance corticosteroid dose of <15 mg of
daily prednisone equivalent and <20 mg of daily prednisone
equivalent both had a significant increase in % predicted
FVC over the 24 weeks. However, both the groups that
received infliximab that had a maintenance corticosteroid
dose of 15 mg of daily prednisone equivalent and had a
maintenance corticosteroid dose of 20 mg of daily pred-
nisone equivalent did not demonstrate a significant change
in % predicted FVC over the 24 weeks.
Fig. 1A shows the relationship between the maintenance
corticosteroid dose and the change in % predicted FVC for
the placebo group. There was no significant correlation
between these two variables. Fig. 1B shows the relationship
between the maintenance corticosteroid dose and the
change in % predicted FVC for the infliximab group. A sig-
nificant negative correlation (Spearman Coefficient
R Z 0.29, p Z 0.0097) was demonstrated between these
two variables such that higher corticosteroid doses were
associated with less improvement in % predicted FVC over
the 24 weeks.Discussion
The main finding of this analysis was that, in a randomized
double blind placebo-control study of infliximab versus
placebo for chronic pulmonary sarcoidosis, the meanTable 2 The change in % predicted FVC between week 0 and
placebo and infliximab groups.
D %pred FVC at
Week 24:
Mean  SE
95% CI, p-value*
Prednisone dose<10 mg
Placebo (N Z 7) 1.87  2.123 (6.37, 2.63), 0.39
Infliximab (N Z 12) 5.59  1.604** (2.19, 8.99), 0.0031
Prednisone dose<15 mg
Placebo (N Z 27) 0.070  1.110 (2.28, 2.14), 0.95
Infliximab (N Z 60) 2.73  0.742 (1.26, 4.21), 0.0004
Prednisone dose<20 mg
Placebo (N Z 32) 0.51  1.066 (2.63, 1.60), 0.63
Infliximab (N Z 65) 3.05  0.747** (1.57, 4.54), <0.0001
FVC: forced vital capacity; *: change from baseline within the group;maintenance corticosteroid dose during the 24 weeks of
infliximab treatment (but not placebo) significantly corre-
lated negatively with improvement in FVC. These data
suggest that higher doses of corticosteroids may blunt the
therapeutic effects of infliximab in the treatment of pul-
monary sarcoidosis. In our analysis examining specific
corticosteroid dose cutoffs, we found that a significant
effect of infliximab, in terms of change of % predicted FVC
at 24 weeks, could be demonstrated whether patients were
on <10 or 10 mg/day of prednisone daily equivalent.
However, at cutoffs of 15 and 20 mg or daily prednisone
equivalent, a significant effect of infliximab on % predicted
FVC could not be demonstrated in those receiving the
higher doses (15 mg and 20 mg).
These findings could possibly be explained by the fact that
one of themechanisms of action corticosteroids in treatment
of sarcoidosis is via TNF-a suppression [10], that is the iden-
tical mechanism of action of infliximab. Corticosteroids
appear to be particularly potent for pulmonary sarcoidosis.
In a study of acute pulmonary exacerbations of sarcoidosis,
20 mg of daily prednisone equivalent for amedian of 3 weeks
was effective in relieving pulmonary symptoms and returning
spirometry to baseline [12]. Even 15 mg of daily prednisone
equivalent was found useful for the treatment of pulmonary
sarcoidosis in a study performed more than 4 decades ago
[13]. It is interesting to speculate that doses of corticoste-
roids at or above 15 mg of daily prednisone equivalent may
inhibit TNF-a to such a degree that potential additional
benefit from infliximab is negligible. Certainly, our analyses
suggest that infliximab was minimally beneficial in patients
who were receiving corticosteroid doses at or above 15mg of
daily prednisone equivalent.
These analyses should be interpreted with caution
because there are several study limitations that are poten-
tially significant. First, these analyses were performed on a
previously conducted prospective, randomized, placebo-
control trial. The issue addressed in this analysis was not a
primary or secondary endpoint of that trial. The trial was not
designed to be adequately powered for our analyses. Some
of the subgroups that we analyzed were of relatively small
sample size, and there is a risk that some of our positive
findings are related to a type I error. Second, we performed
multiple analyses that may have also artificially increasedweek 24 stratified by maintenance prednisone dose in the
D %pred FVC at
Week 24:
Mean  SE
95% CI, p-value*
Prednisone dose ‡10 mg
Placebo (N Z 35) 0.029  1.054 (2.06, 2.12), 0.98
Infliximab (N Z 68) 2.10  0.756 (0.60, 3.60), 0.0064
Prednisone dose ‡15 mg
Placebo (N Z 15) 0.53  1.880 (4.36, 3.29), 0.78
Infliximab (N Z 20) 2.20  1.628 (1.12, 5.52), 0.19
Prednisone dose ‡20 mg
Placebo (N Z 10) 0.44  2.183 (4.09, 4.97), 0.84
Infliximab (N Z 15) 0.77  1.777 (2.91, 4.46), 0.67
**: p < 0.01 infliximab versus placebo.
Figure 1 A. The relationship between the maintenance
corticosteroid dose and the change in % predicted FVC for the
placebo group. B. The relationship between the maintenance
corticosteroid dose and the change in % predicted FVC for the
infliximab group.
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groups that we identified were not similar in a few respects.
More black subjects were in the >15 mg of prednisone and
>20 mg of prednisone than in their counterpart lower
prednisone dose groups (Table 1). Although this may suggest
that the differences in the response to infliximab relate to
race, this was specifically examined in the original infliximab
trial andwas found not to be the case [1]. The less prominent
lung opacities as determined by R-score in these two high
prednisone dose subgroups actually conforms to our hy-
pothesis. Specifically, the effect of high dose corticosteroids
likely improved pulmonary sarcoidosis significantly to lower
the R-score so that there was less residual disease (or
inflammation as reflected by the R-score) that was poten-
tially treatable with infliximab. In addition, the hypothesis
that higher doses of prednisone blunt the response to
infliximab was supported by two different analyses: the
response above and below different doses of corticosteroids
(Table 2) and the negative correlation between the change in
FVC% with infliximab treatment and the concurrent dose of
prednisone (Fig. 1B).
Given the above limitations, these analyses should be
considered hypothesis-generating and have potentially
important clinical implications. These data suggest that
infliximab is of limited use for pulmonary sarcoidosis pa-
tients receiving corticosteroid doses above the 15e20
prednisone daily equivalent range. If our supposition is cor-
rect that suppressing TNF-a caused by higher dose cortico-
steroids explains these findings, it would suggest that such
patients, if they truly continue to have active pulmonary
disease, should be considered for alternative therapies that
do not involve blockade of the TNF-a pathway. Since a pre-
vious large retrospective study suggested that infliximab is
superior to corticosteroids alone for the treatment of lupus
pernio form of skin sarcoidosis [14], our results lend support
to the notion that the efficacy of anti-sarcoidosis medication
may be dependent on the specific organ involved.
In summary, our results suggest that infliximab adds
minimal potential benefit to corticosteroid therapy for pul-
monary sarcoidosis on corticosteroid doses above 15e20mg/
day of prednisone equivalent. Although a study is unlikely to
be performed that directly addresses the additional benefit
of a compound above the corticosteroid effect in sarcoidosis,
this issue could be examined in sarcoidosis clinical trials via a
corticosteroid withdrawal phase.Conflicts of interest
MAJ: consultant for Janssen, Celgene, Norvarits; RPB:
research grants from Janssen, Celgene, Pfizer, Gilead,
Forest, consultant for Janssen, Celgene, Novartis; UC:
consultant for Janssen; MM and ESB are employees of and
own stock in Johnson & Johnson, parent company of Jans-
sen R&D.Acknowledgments
Guarantor statement: Dr. Marc A. Judson takes re-
sponsibility for the content of the manuscript, including the
data and analysis.
194 M.A. Judson et al.Author contributions: MAJ, RPB, UC, EB: overall design,
assisted in the writing and editing of the manuscript, was
involved in statistical investigations; MM: assisted in the
writing and editing of the manuscript, was involved in
statistical investigations and performed the statistical
analyses.
Financial/non-financial disclosures: MAJ: consultant
for Janssen, Celgene, Norvarits; RPB: research grants from
Janssen, Celgene, Pfizer, Gilead, Forest, consultant for
Janssen, Celgene, Novartis; UC: consultant for Janssen; MM
and ESB are employees of and own stock in Johnson &
Johnson, parent company of Janssen R&D.
Role of sponsors: This study was not funded.
Other contributions: The authors wish to acknowledge
Sooyeon Kwon, PhD for her expert assistance with the ta-
bles used in this manuscript.
References
[1] Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du
Bois R, et al. Infliximab therapy in patients with chronic
sarcoidosis and pulmonary involvement. Am J Respir Crit Care
Med 2006;174(7):795e802.
[2] Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH,
Kavuru MS, et al. Efficacy of infliximab in extrapulmonary
sarcoidosis: results from a randomised trial. Eur Respir J 2008;
31(6):1189e96.
[3] Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E,
Pabst R, et al. Alveolar macrophages are the main source for
tumour necrosis factor-alpha in patients with sarcoidosis. Eur
Respir J 2003;21(3):421e8.
[4] Zissel G, Muller-Quernheim J. Sarcoidosis: historical perspec-
tive and immunopathogenesis (part I). Respir Med 1998;92(2):
126e39.[5] Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J
Med 2007;357(21):2153e65.
[6] Grutters JC, van den Bosch JM. Corticosteroid treatment in
sarcoidosis. Eur Respir J 2006;28(3):627e36.
[7] Hunninghake GW, Costabel U, Ando M, Baughman R,
Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on
sarcoidosis. American Thoracic Society/European Respiratory
Society/World Association of Sarcoidosis and other Granulo-
matous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;
16(2):149e73.
[8] Judson MA. The treatment of pulmonary sarcoidosis. Respir
Med 2012;106:1351e61.
[9] Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and
emerging pharmacological treatments for sarcoidosis: a re-
view. Drug Des Devel Ther 2013;7:325e38.
[10] Adcock IM, Ito K. Molecular mechanisms of corticosteroid ac-
tions. Monaldi Arch Chest Dis 2000;55(3):256e66.
[11] Muers MF, Middleton WG, Gibson GJ, Prescott RJ, Mitchell DN,
Connolly CK, et al. A simple radiographic scoring method for
monitoring pulmonary sarcoidosis: relations between radio-
graphic scores, dyspnoea grade and respiratory function in the
British Thoracic Society Study of Long-Term Corticosteroid
Treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997;14(1):
46e56.
[12] McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of
short-course, low-dose corticosteroid therapy for acute pul-
monary sarcoidosis exacerbations. Am J Med Sci 2010;339(1):
1e4.
[13] Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone
treatment of sarcoidosis. Am Rev Respir Dis 1973;107(4):
609e14.
[14] Stagaki E, Mountford WK, Lackland DT, Judson MA. The
treatment of lupus pernio: results of 116 treatment courses in
54 patients. Chest 2009;135(2):468e76.
